



FOR IMMEDIATE RELEASE

## **Cancer Prevention Pharmaceuticals (CPP) To Present At BIO CEO & Investor Conference in NYC**

### ***CPP seeking approval in US and in EU for rare disease drug candidate***

TUCSON, Arizona, February 4, 2020 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a private biotech company developing novel therapeutics to prevent cancer and other diseases, announced today that CEO Jeff Jacob will provide an update of the company’s drug development pipeline during the 22<sup>nd</sup> Annual BIO CEO & Investor Conference, February 10 – 11, 2020, at the New York Marriott Marquis.

Mr. Jacob’s presentation will be Monday, February 10<sup>th</sup> at 1:45 PM in the Ziegfeld Room of the Marriott Marquis.

CPP’s lead drug candidate is CPP-1X/sul for the treatment of adults with familial adenomatous polyposis (FAP). FAP is a rare genetic disease that if left untreated progresses to colorectal cancer in nearly 100% of patients. FAP patients have no approved pharmaceutical therapies.

CPP recently completed its FAP-310 clinical trial, a Phase 3 clinical trial comparing the performance of the combination of CPP-1X (eflornithine) and sulindac (sul) to each single agent alone in delaying progression to an FAP-related event, such as surgery. The safety profile of the combination did not significantly differ from that demonstrated by the single agents and did not pose any concerns for long-term use of the product. CPP is seeking regulatory pathways for approval in the US and EU.

“Approval of CPP-1X/sul could mean the only approved pharmaceutical treatment for FAP patients, to delay or prevent surgeries or endoscopic excisions” said Mr. Jacob.

CPP recently announced the extension of a long-term agreement with Sanofi, a French multinational pharmaceutical company, to continue as the exclusive supplier of CPP-1X/sul. The agreement extended the 10-year supplier relationship through the regulatory submission process and for at least six years after approval of the drug.

#### **About Cancer Prevention Pharmaceuticals, Inc.**

Cancer Prevention Pharmaceuticals, Inc. (CPP) is developing therapeutics designed to reduce the risk of cancer and other diseases. CPP’s pharmaco-prevention approach has been used with success in other disease categories such as cardiovascular, neurovascular, and infectious disease. In addition to the CPP FAP-310 trial, CPP is co-sponsoring with the National Cancer Institute (NCI) and SWOG a large Phase 3 trial in colon cancer survivors. CPP is also working collaboratively with nonprofit groups to support their clinical trials in neuroblastoma, gastric



cancer, and early-onset type 1 diabetes. CPP is located in Tucson, Arizona. For more information, please visit [www.canprevent.com](http://www.canprevent.com).

*This press release contains forward looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward looking statements include statements that approval of CPP-1X/sul could mean the first effective treatment for FAP patients who now have limited therapeutic options. These forward looking statements represent the company's judgment as of the date of this release. The company disclaims, however any intent or obligation to update these forward looking statements.*

**Investor Relations Contact:** Amato and Partners, LLC, Investor Relations Counsel,  
[admin@amatoandpartners.com](mailto:admin@amatoandpartners.com)

**Media:** Christine Brannen, Cancer Prevention Pharmaceuticals, Inc., [press@canprevent.com](mailto:press@canprevent.com),  
+1.520.908.7774

###